



PHARMA PRESCRIBED .COM

NEWSLETTER · IN CONVERSATION WITH NURIA COLL-BASTUS

Matched to a trial in five minutes

Nuria Coll-Bastus — onco-genomics scientist turned founder of ClinicalNet — on the recruitment bottleneck that delays most trials, and building a platform to match patients in minutes rather than months.

Nuria Coll-Bastus came to clinical research the long scientific way — a chemistry degree in Barcelona, then cancer therapeutics and onco-genomics — before turning founder. Born in Spain and now based in the UK, she built ClinicalNet, a health-tech startup with a deceptively simple aim: match patients to the right trial in under five minutes.



Eighty percent of trials are delayed by recruitment. That's the problem I want to delete.

— Nuria Coll-Bastus, on Pharma Prescribed

The bottleneck nobody solved

Recruitment is the quiet reason so many trials run late — roughly four in five are delayed by it, at a cost measured in billions and, more importantly, in patients who never find the study that might help them. Nuria's argument is that this is an access-and-data problem, not an immovable fact of nature.

Automating the match

ClinicalNet's answer is to automate access and centralise the data, so both patients and practitioners can find each other quickly rather than relying on chance, geography and paperwork. Bringing a cross-cultural lens — Spain and the UK, academia and industry — she's designing for a global problem rather than a single market's quirks.

From bench to platform

Her onco-genomics background isn't incidental. Having worked close to the science, she knows how precise modern eligibility has become — and how cruel it is when a patient who fits a trial never hears about it. The platform is, in effect, an attempt to make that precision reach the people it was built for.



Listen to the full episode

Nuria Coll-Bastus on Pharma Prescribed — at pharmaprescribed.com
and wherever you get your podcasts.

Nuria Coll-Bastus *is the founder of ClinicalNet, with a background in drug development and onco-genomics.*